Prevention of the relapses, therapy of minimal residual disease as multiple melanoma, immunochemical relapse with rapid increase of paraprotein.

Diseases include: ovarian, breast, colon, stomach, kidney cancers, melanoma, bladder, liver cancer, cholangiocarcinoma

Therapy principle: the therapy employs individually tailored autologous (patient’s own) cell products: anti-tumor dendritic vaccines and/or cytostatic lymphocytes.  The cell product is prepared from the cells of the patient and tumor proteins. The monocytes (for dendritic cells) and lymphocytes are isolated from the patient’s PBMCs harvested on a separator or from the whole blood. The cells are expanded in the laboratory and incubated with tumor antigens to obtain the specific cell subpopulations and mature dendritic cells that provide the basis for immunotherapy. The individually tailored cell vaccines and cytotoxic lymphocytes are administered with an interval of two to four weeks depending on the type of the disease, its status and risk group for 6 to 12 months. The efficiency of the immunotherapy is evaluated by the levels of specific paraprotein. To prepare the cell immune products it takes five days for dendritic vaccine and two to three weeks for cytotoxic T lymphocytes. The source of the tumor antigen is the patient’s paraproteins. For it, it is necessary to acquire the plasma samples of the patient before the chemotherapy, when the levels of paraprotein is maximal.

Result: Arrest of the progress of cancer and immune prevention of its relapses.